Table 4.

Acute adverse events and grade for concurrent chemotherapy

Event for acute chemotherapy toxicity	Taxane combined platinum-based concurrent chemoradiotherapy N = 104
	All grades	Grade 1	Grade 2	Grade 3	Grade 4	Grade 5
Leukopenia	72 (69.2%)	30 (28.8%)	32 (30.8%)	9 (8.7%)	1 (1.0%)	0 (0.0%)
Neutropenia	37 (35.6%)	13 (12.5%)	16 (15.4%)	4 (3.8%)	4 (3.8%)	0 (0.0%)
Anemia	35 (33.7%)	34 (32.7%)	1 (1.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Thrombocytopenia	6 (5.8%)	5 (4.8%)	1 (1.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Hyper creatinine	3 (2.9%)	3 (2.9%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Total bilirubin elevation	17 (16.3%)	12 (11.5%)	5 (4.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Conjugated bilirubin concentration elevation	16 (15.4%)	10 (9.6%)	6 (5.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Unconjugated bilirubin concentration elevation	16 (15.4%)	11 (10.6%)	5 (4.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Hyponatremia	21 (20.2%)	17 (16.4%)	4 (3.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Hypochloremia	19 (18.3%)	16 (15.4%)	3 (2.9%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Hypokalemia	19 (18.3%)	15 (14.4%)	3 (2.9%)	1 (1.0%)	0 (0.0%)	0 (0.0%)
Nasopharyngeal wall necrosis	3 (3.5%)	0 (0.0%)	1 (2.4%)	0 (0.0%)	0 (0.0%)	2 (2.4%)
Eye damage	16 (18.8%)	13 (15.3%)	3 (13.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Deafness	43 (50.6%)	17 (20%.0)	21 (24.7%)	4 (4.7%)	1 (1.2%)	0 (0.0%)
Trismus	11 (12.9%)	5 (5.9%)	5 (5.9%)	1 (1.2%)	0 (0.0%)	0 (0.0%)
Xerostomia	57 (67.1%)	30 (35.3%)	26 (30.6%)	1 (1.2%)	0 (0.0%)	0 (0.0%)
Skin damage	29 (34.1%)	23 (27.1%)	6 (7.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Dysphagia	15 (17.6%)	13 (15.3%)	2 (2.4%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Temporal-lobe necrosis	17 (20.0%)	16 (18.8%)	1 (1.2%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

^§85 patients were included in the safety analysis due to the death or loss of patients

All data are presented as No. (%). Percentage values are rounded